DUS2抗体

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Western blot analysis using TACSTD2 mouse mAb against A431 (1), HCT116 (2), PC-3 (3), MCF-7 (4), SK-Br-3 (5), T47D (6), HEK293 (7), and HEK293-6e (8) cell lysate.    

  
  

•  

   

     Flow cytometric analysis of BEL-7402 cells using TACSTD2 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Flow cytometric analysis of HepG2 cells using TACSTD2 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human cervical cancer tissues using TACSTD2 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human esophageal cancer tissues using TACSTD2 mouse mAb with DAB staining.    

  
  

DUS2 (Dihydrouridine Synthase 2), also known as Dus2-like protein, is an enzyme belonging to the dihydrouridine synthase family, which plays a critical role in post-transcriptional RNA modification. It catalyzes the reduction of uridine to dihydrouridine (D) in specific tRNA molecules, a conserved modification that enhances tRNA flexibility and stability, thereby influencing translational efficiency and accuracy. Dysregulation of DUS2 has been implicated in various cellular processes, including stress response and protein synthesis, with potential links to human diseases such as cancer and neurological disorders.

Antibodies targeting DUS2 are essential tools for studying its expression, localization, and functional mechanisms. They enable researchers to investigate DUS2's role in RNA metabolism, its interaction with tRNA substrates, and its tissue-specific distribution. Such antibodies are typically validated in applications like Western blotting, immunohistochemistry, and immunofluorescence. Recent studies have explored DUS2's overexpression in certain cancers, suggesting its utility as a biomarker or therapeutic target. However, the precise molecular pathways and clinical relevance of DUS2 remain under active investigation, highlighting the importance of reliable antibody reagents in advancing this field.